Discovery of novel 2-aryl-3-sulfonamido-pyridines (HoAns) as microtubule polymerization inhibitors with potent antitumor activities.

[1]  N. O’Boyle,et al.  Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review , 2020, Pharmaceuticals.

[2]  Duane D. Miller,et al.  Structure Activity Relationships Study of Novel 6 Aryl-2-Benzoyl-Pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties. , 2019, Journal of medicinal chemistry.

[3]  F. Dehghani,et al.  The Cytoskeleton—A Complex Interacting Meshwork , 2019, Cells.

[4]  J. Klaunig.  Oxidative Stress and Cancer. , 2019, Current pharmaceutical design.

[5]  C. Chou,et al.  Honokiol, a Polyphenol Natural Compound, Attenuates Cisplatin-Induced Acute Cytotoxicity in Renal Epithelial Cells Through Cellular Oxidative Stress and Cytoskeleton Modulations , 2018, Front. Pharmacol..

[6]  She Chen,et al.  Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells , 2018, Cell Research.

[7]  N. Meanwell.  Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. , 2018, Journal of medicinal chemistry.

[8]  S. Horwitz,et al.  Taxol®: The First Microtubule Stabilizing Agent , 2017, International journal of molecular sciences.

[9]  P. Meraldi,et al.  The Elephant in the Room: The Role of Microtubules in Cancer. , 2017, Advances in experimental medicine and biology.

[10]  U. Abdu,et al.  Regulation of long-distance transport of mitochondria along microtubules , 2017, Cellular and Molecular Life Sciences.

[11]  G. Basso,et al.  Vascular disrupting activity of combretastatin analogues. , 2016, Vascular pharmacology.

[12]  J. Tuszynski,et al.  Analysis of the binding mode of laulimalide to microtubules: Establishing a laulimalide–tubulin pharmacophore , 2016, Journal of biomolecular structure & dynamics.

[13]  Caroline Delandre,et al.  Microtubule nucleation and organization in dendrites , 2016, Cell cycle.

[14]  A. Jimeno,et al.  Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer , 2016, Journal of clinical pharmacology.

[15]  C. Teng,et al.  N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling. , 2015, Journal of medicinal chemistry.

[16]  Thomas Sander,et al.  DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis , 2015, J. Chem. Inf. Model..

[17]  J. Maris,et al.  Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621) , 2014, Pediatric Blood & Cancer.

[18]  A. Schnittger,et al.  Cell cycle control across the eukaryotic kingdom. , 2013, Trends in cell biology.

[19]  K. Sinha,et al.  Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis , 2013, Archives of Toxicology.

[20]  E. Dmitrovsky,et al.  A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients , 2012, Chemotherapy.

[21]  F. Giles,et al.  ELR510444, A Novel Microtubule Disruptor with Multiple Mechanisms of Action , 2011, Journal of Pharmacology and Experimental Therapeutics.

[22]  E. Ashton,et al.  Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas , 2010, Clinical Cancer Research.

[23]  S. Remick,et al.  Combretastatin A4 phosphate: a novel vascular disrupting agent. , 2010, Future oncology.

[24]  Marcel Knossow,et al.  The binding of vinca domain agents to tubulin: structural and biochemical studies. , 2010, Methods in cell biology.

[25]  Raimond B G Ravelli,et al.  Variations in the colchicine-binding domain provide insight into the structural switch of tubulin , 2009, Proceedings of the National Academy of Sciences.

[26]  E. Schwartz.  Antivascular Actions of Microtubule-Binding Drugs , 2009, Clinical Cancer Research.

[27]  E. Pasquier,et al.  Microtubules: A dynamic target in cancer therapy , 2008, IUBMB life.

[28]  Seamus J. Martin,et al.  Caspase activation cascades in apoptosis. , 2008, Biochemical Society transactions.

[29]  G. Stark,et al.  Control of the G2/M transition , 2006, Molecular biotechnology.

[30]  E. Nogales,et al.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Jaén,et al.  Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[33]  A. Levine,et al.  The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells , 1998, Oncogene.

[34]  A. Yamaguchi,et al.  Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. , 1997, Cancer research.

[35]  F. Solomon,et al.  Microtubule Function in Morphological Differentiation: Growth Zones and Growth Cones , 1997, Cell.

[36]  T. Nagasu,et al.  In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. , 1994, Cancer research.

[37]  D. Sackett,et al.  Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin. , 1993, Biochemistry.

[38]  T. Mitchison.  Microtubule dynamics and kinetochore function in mitosis. , 1988, Annual review of cell biology.

[39]  T. MacRae,et al.  N,N'-Ethylene-bis(iodoacetamide) as a probe for structural and functional characteristics of brine shrimp, squid, and bovine tubulins. , 1985, Canadian journal of biochemistry and cell biology = Revue canadienne de biochimie et biologie cellulaire.